期刊文献+

偏头痛的合理用药 被引量:9

Pharmacological management of migraine
原文传递
导出
摘要 偏头痛的治疗应遵循个体化治疗,同时结合对患者的宣教和其他非药物干预措施。急性期治疗包括普通止痛剂(非甾体抗炎药)和偏头痛特异性药物(麦角胺和曲坦类),药物使用应遵循阶梯法或分层法原则。对需要进行预防治疗的患者,可按照个体情况选择氟桂利嗪、抗抑郁剂(阿米替林)、抗癫痫剂(丙戊酸和托吡酯)及β受体阻滞剂(心得安和美托心安),疗效评估4~8周,疗程3~6个月。 Pharmacological management of migraine should be evidence-based and individualized, combined with patient's education and non-pharmacological management. For acute therapy,simple or combination analgesics (non-steroidal anti-inflammatory drugs) or migraine specific drugs (ergotamines and triptans) are recommended and should be administrated following the concept of stratification or stepwise treatment. For preventive therapy, flunarizine, antidepressant ( amitriptyline), antiepilepties (valproic acids and topiramate), and beta-blockers (propranolol and metoprolol ) are drugs of first choice and should be chosen individually. Prophylaxis therapy should be evaluated for 4 - 8 weeks and last for 3 --6 months whenever it is effective.
作者 李焰生
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2010年第6期495-497,共3页 Chinese Journal of Practical Internal Medicine
关键词 偏头痛 麦角胺 曲坦类 migraine ergotamine triptans
  • 相关文献

参考文献5

  • 1Goadsby PJ, Lipton RB, Ferrari MD. Migraine : Current understanding and treatment [ J ]. NEJM,2004,346 : 257 - 270.
  • 2偏头痛诊断与防治专家共识组,李焰生.偏头痛诊断与防治专家共识[J].中华内科杂志,2006,45(8):694-696. 被引量:322
  • 3Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache ( an evidence-based review) : report of the quality standards subcommittee of the American academy of neurology for the United States headache consortium [ J ]. Neurology, 2000, 55:754 - 762.
  • 4Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force [ J ]. Eur J Neurol,2009,16:968 - 981.
  • 5Stewart WF,Lipton RB,Sawyer J. An international study to assess the reliability of the Migraine Disability Assessment ( MIDAS ) score[ J ]. Neurology, 1999,53:988 - 994.

二级参考文献10

  • 1Lipton RB,Diamond S,Reed M,et al.Migraine diagnosis and treatment:results from the American Migraine Study Ⅱ.Headache,2001,41:638-645.
  • 2Silberstein SD.Practice parameter:evidence-based guidelines for migraine headache (an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology,2000,55:754-762.
  • 3Ferrari MD,Roon KI,Lipton RB,et al.Oral triptans (serotonin 5-HT(1B/1 D) agonists) in acute migraine treatment:a meta-analysis of 53 trials/ Lancet,2001,358:1668-1675.
  • 4Headache Classification Subcommittee of the International Headache Society.The Internatiional Classificatiion of Headache Disorders:2nd edition.Cephalalgia,2004,24 Suppl 1:9-160.
  • 5Lawrence EC.Diagnosis and management of migraine headaches.South Med J,2004,97:1069-1077.
  • 6Goadsby PJ,Lipton RB,Ferrari MD.Migraine-current understanding and treatment.N Engl J Med,2002,346:257-270.
  • 7Lipton RB,Stewart WF,Stone AM,et al.Stratified care vs step care strategies for migraine:the Disablility in Strategies of Care(DISC) Study:A randomized trial.JAMA,2000,284:2599-2605.
  • 8Lipton RB,Bigal ME.Migraine:epidemiology,impact,and risk factors for progression.Headache,2005,45:Suppl 1:S3-S13.
  • 9Silberstein SD,Rosenberg J.Multispecialty consensus on diagnosis and treatment of headache.Neurology,2000,54:1553.
  • 10Snow V,Weiss K,Wall EM,et al.Pharmacologic management of acute attacks of migraine and prevention of migraine headache.Ann Intern Med,2002,137:840-849.

共引文献321

同被引文献55

引证文献9

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部